⌕
Aurinia Pharmaceuticals · AUPH · Nasdaq
Tenet 82 · Strong
Compare
$15.40−0.52%At closeTenet 82 · Strong
$15.40−0.08 (−0.52%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Aurinia Pharmaceuticals (AUPH) Stock

Aurinia Pharmaceuticals (AUPH) closed at $15.40 on Nov 17, 2026; its Tenet Score is 82 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

8 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$15.40
Nov 17, 2026
Market cap
$2.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
6.7×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
13.52 – 19.25
low → high · as of close, Nov 16, 2026
Tenet Score
82/100
Strong · 340 Healthcare peers

Industry: Drugs

Aurinia Pharmaceuticals Inc scores 82/100. Strong. Strongest on growth and value, trading at 7× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
82/ 100
Strong
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
84
Quality
71
Health
82
Growth
92

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityBHealthBGrowthAMomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
3.2×
Sep 30, 2026 balance sheet
P/S
6.4×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
61%
TTM through Sep 30, 2026
Operating margin
37.1%
fiscal 2025, before interest and tax
Net margin
—
Withheld: this figure is outside the range we accept for its kind.
Current ratio
6.12
Sep 30, 2026 balance sheet
Net debt / EBITDA
−2.9×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the t…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 86 US ETFs · top wrappers by weightSee all ETFs holding AUPH →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Aurinia Pharmaceuticals in?

Aurinia Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Aurinia Pharmaceuticals' Tenet Score?

Aurinia Pharmaceuticals' Tenet Score is 82 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.